Evidence map›Paper›PMID 37897303›Full record

ArticleJournal of veterinary internal medicine

Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia.

Sandra M Axiak-Bechtel, Stacey B Leach, Jessica R Newton-Northup, Rowan J Milner, Stacey A Fox-Alvarez, Lana I Fagman, Kaylee A Young, Deborah J Tate, Zachary M Wright, John D Chretin and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 1 country.

Sandra M Axiak-BechtelDepartment of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0002-7773-5959
Stacey B LeachDepartment of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA.ORCID https://orcid.org/0000-0001-7538-9071
Jessica R Newton-NorthupTCI Peptide Therapeutics, Columbia, Missouri, USA.
Rowan J MilnerDepartment of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0001-6379-2058
Stacey A Fox-AlvarezDepartment of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.
Lana I FagmanDepartment of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.
Kaylee A YoungDepartment of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.
Deborah J TateDepartment of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA.
Zachary M WrightVCA Animal Diagnostic Clinic, Dallas, Texas, USA.
John D ChretinVCA West Los Angeles, Los Angeles, California, USA.
Justin W AllenVCA West Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-2881-0542
Sean K YoshimotoVCA West Los Angeles, Los Angeles, California, USA.
Kimberly A SeltingDepartment of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA.
Brian K FlesnerDepartment of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA.
Carrie R WhiteVCA Family and Oahu Veterinary Specialty Center, Pearl City, Hawaii, USA.
Tracy MillsVCA Clinical Studies, Los Angeles, California, USA.
Michael AherneDepartment of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.ORCID https://orcid.org/0000-0001-9599-9256
Philip J BergmanVCA Clinical Studies, Los Angeles, California, USA.
LeAnn QiTCI Peptide Therapeutics, Columbia, Missouri, USA.
Kenneth A GruberTCI Peptide Therapeutics, Columbia, Missouri, USA.
Michael F CallahanDepartment of Medical Pharmacology & Physiology and the Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri, USA.
University of Florida · USMissouri College · USTCI Peptide Therapeutics (United States) · USWest Los Angeles College · USMuseum of Contemporary Art, Los Angeles · USAustin Diagnostic Clinic · USUniversity of Hawaii–West Oahu · USUniversity of Illinois Urbana-Champaign · USUniversity of Missouri · US

Funding

Development of a Cancer Cachexia TherapeuticR44CA210763 · NCI · TENSIVE CONTROLS, INC. · PI GRUBER, KENNETH ALLEN · 2016 to 2018
$2.5M
Melanocortin Ligands in Disease CachexiaR44CA150703 · NCI · TENSIVE CONTROLS, INC. · PI GRUBER, KENNETH ALLEN · 2012 to 2013
$1.7M
Melanocortin Ligands in Disease CachexiaR43CA150703 · NCI · TENSIVE CONTROLS, INC. · PI GRUBER, KENNETH ALLEN · 2010 to 2010
$199k
NCI NIH HHS R43 CA150703NCI NIH HHS R44 CA150703NCI NIH HHS R44 CA210763
6 · The paper itself

Abstract

backgroundThe melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy beagle dogs. HYPOTHESIS/

objectivesThe objectives of this study were to investigate the safety, peak plasma concentrations, and potential for efficacy of TCMCB07 in pet dogs with naturally occurring cachexia over a 4-week time period. ANIMALS: Fourteen dogs with cachexia of any underlying cause, except cancer of the oral cavity or gastrointestinal tract, were eligible for enrollment with informed client consent.

methodsThis study was a prospective, 1-armed open-label trial. Physical examination, complete blood count, chemistry panel, and owner-assessed quality of life surveys were checked at weeks 1, 2, and 4. Due to potential for bradycardia and hypotension, Holter monitoring and blood pressure evaluations were scheduled at pre-enrollment and week 4.

resultsFourteen dogs completed the trial. Significant changes detected included increased mean body weight (18.6-19.5 kg, P < .02), increased body condition score (median Tufts 5-point thin dog scale score P < .004 and WSAVA muscle condition score P < .02) and increased mean blood urea nitrogen (21.79-30.43 mg dL CONCLUSIONS AND CLINICAL IMPORTANCE: TCMCB07 was safe and has potential efficacy in pet dogs with cachexia.

Indexed as

Dog DiseasesNeoplasmsAnimalsCachexiaDogsHumansMelanocortinsPeptidesProspective StudiesQuality of LifeMelanocortinsPeptidesanorexiacanineemaciationmetabolismtherapy

Identifiers

PMID37897303
PMCPMC10658582
OpenAlexW4388001205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.